1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSmall Business Innovation Research (SBIR) Phase IIB Small Market Awards is sponsored by National Heart, Lung, and Blood Institute (NHLBI). Aims to accelerate the commercialization of technologies for heart, lung, blood, and sleep disorders.
Get alerted about grants like this
Get emailed when new opportunities from “National Heart, Lung, and Blood Institute (NHLBI)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NHLBI Small Business Program | NHLBI, NIH NHLBI Small Business Program NHLBI Small Business Program The NHLBI is interested in Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) activities that advance the prevention, diagnosis, and treatment of heart, lung, blood, and sleep disorders.
Below is a list of funding opportunity announcements that offer small business entrepreneurs a chance to obtain funding without requirements to give up equity or ownership for early-stage research and development. Get answers to frequently asked questions about the NHLBI Small Business Program .
Learn more about the Innovation and Commercialization Office (I&C) , which coordinates the institute’s Small Business Program, offers services to SBIR/STTR applicants and awardees, provides digital education and online resources, and supports other SBIR/STTR awardee opportunities. Small Business Program Coordinator Julia Berzhanskaya, Ph. D.
NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed) SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required) Notice of Special Interest (NOSI): Small Business Initiatives for Innovative tools and Technologies for Improving Outcomes for Maternal Health Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed) Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required) Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required) Notice of NHLBI Participation in NOT-AI-24-007 "Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH)" Notice of Special Interest (NOSI): Translating Biomaterials-Based Technologies to Commercially Viable Products Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence/Machine Learning Tools for Improved Assessment in Biomedical and Behavioral Research Notice of Special Interest (NOSI): Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health Notice of Special Interest: Womens Health Research Notice of Special Interest (NOSI): Development of Functional Assay Sites to Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44) Innovation and Commercialization Office NHLBI's Small Business Program Frequently Asked Questions Small Business and Academic Innovation Success Stories NIH's Small Business Education and Entrepreneurial Development (SEED) website Innovation and Commercialization Office Inquiry Form
According to the current listing, eligibility includes: Small businesses developing technologies for heart, lung, blood, and sleep disorders. Confirm the full requirements in the official notice before applying.
Small Business Innovation Research (SBIR) Phase IIB Small Market Awards is funded by National Heart, Lung, and Blood Institute (NHLBI). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
HeartShare 2.0: Refining Heart Failure Subtypes and Treatment Targets for Personalized Clinical Trials - Clinical Trial Center and Clinical Centers (U01 Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI), NIH. Supports clinical trial centers and clinical centers for refining heart failure subtypes and treatment targets for personalized clinical trials.
Growing Data-science Research in Africa to Stimulate Progress (GRASP) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. The GRASP program supports data-science research in Africa to stimulate progress. While the provided information is an award notice, it indicates an active program with a performance end date in July 2026, suggesting ongoing or upcoming related opportunities. The NIH supports a diverse mix of research projects in Sub-Saharan Africa.
NHLBI Program Project Applications (P01 Clinical Trials Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI). This funding opportunity supports comprehensive, often multidisciplinary, research projects focused on heart, lung, blood, and sleep conditions and diseases. Each application must include at least three related research projects sharing a common theme.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
The $46M FSHARP program is creating shelf-stable synthetic blood from freeze-dried components. A new SWiFT SBIR topic opened May 6 for autonomous field transfusion devices. What grant seekers in biomedical engineering need to know.
Read articleDARPA MTO opened six FY26 SBIR topics on May 27 with a June 24 deadline — nanopore proteomics, compact RF filters, 800°C ICs, passive thermal spreaders, radiation-hardened codesign, and low-resource computing. The topics read like a wishlist for the next decade of contested-environment microelectronics. Here is what each one is actually asking for, and how small businesses should triage the four-week window.
Read article